Hard to Treat Diseases (HTDS) Collagenna Skin Care Products Exhibits at Canada's Largest Professional Esthetics and Spa Show

Jun 02, 2010, 06:00 ET from Hard to Treat Diseases

OTTAWA, June 2 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) Collagenna Skin Care Products participated at the Esthetique Spa International Trade Show this past May 30 & 31 in Toronto, Ontario. www.spa-show.com

Collagenna Skin care Products Inc. presented its line of products to Esthetic and Spa Professionals over the past 2 days in Toronto Canada. This show is a professional trade show open only to industry professional and the initial attendance figures are estimated at around 7500 visitors. Collagenna Skin Care Products used the opportunity to present its new products such as the DermaResolve (TM) Peptide Serum as well as the Cellulite reducing Alphaderm Cream.

Collagenna's Ontario District Sales Manager, Jerry Stepkoff states "This show was very well attended and we are pleasantly surprised by the enquiries we received regarding our line. For the second year in a row we were fortunate enough to have some of our existing clients come and help us in our booth. It is always effective when a prospect can actually meet somebody who is using the product line and is willing to share their experiences. We sensed that the mood of the crowd was more positive than in the past year and we expect to generate some new sales as a result of this show."

In other news, Collagenna Skin Care Products has hired Mr. Don Ginn of St Louis, Missouri as its new Regional Sales Manager. Mr Ginn brings with him many years of experience in the field of peptide sales and he has decided to join our staff and help us develop distribution channels in the Mid-Western States. His nomination will take place immediately.

The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.Com Filing Service. Its IR company web site section "CLIENT SUPPORT" TAB www.minamargroup.net or this direct link http://minamarmarketinggroup.helpserve.com/ should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support sites to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link www.minamargroup.net/helpdesk.

To be included in the company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at www.minamargroup.com/updates.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk

SOURCE Hard to Treat Diseases